Restoring RNA Fidelity Through Antisense Innovation

At Stitch, we are redefining how neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) are treated — not by masking symptoms, but by directly repairing the disrupted genetic messages that drive neuronal degeneration.

Our platform unites antisense oligonucleotide (ASO) therapeutics and theranostic biomarkers into a single, closed-loop system — enabling the design, optimization, and clinical validation of precision RNA-targeted medicines for TDP-43 proteinopathies.